c52B8

N/A

Report date: 2022/07/01 15:29:28

Base Information

Drug Namec52B8
Drug Alias Namec-52-B-8
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-Leukocyte immunoglobulin-like receptor subfamily B member 4
TargetsLeukocyte immunoglobulin-like receptor subfamily B member 4
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMerck & Co
China Registration ClassN/A

Develop Information

Active CompaniesMerck & Co
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A